IN2014MN02213A - - Google Patents

Info

Publication number
IN2014MN02213A
IN2014MN02213A IN2213MUN2014A IN2014MN02213A IN 2014MN02213 A IN2014MN02213 A IN 2014MN02213A IN 2213MUN2014 A IN2213MUN2014 A IN 2213MUN2014A IN 2014MN02213 A IN2014MN02213 A IN 2014MN02213A
Authority
IN
India
Prior art keywords
formulations
incision
infiltration
api
administered
Prior art date
Application number
Other languages
English (en)
Inventor
Shimon Amselem
Michael Naveh
Original Assignee
Painreform Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Painreform Ltd filed Critical Painreform Ltd
Publication of IN2014MN02213A publication Critical patent/IN2014MN02213A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Botany (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN2213MUN2014 2012-05-10 2013-05-09 IN2014MN02213A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261645066P 2012-05-10 2012-05-10
US201261649400P 2012-05-21 2012-05-21
US201361781595P 2013-03-14 2013-03-14
US201361781625P 2013-03-14 2013-03-14
PCT/IL2013/050404 WO2013168167A1 (en) 2012-05-10 2013-05-09 Depot formulations of a hydrophobic active ingredient and methods for preparation thereof

Publications (1)

Publication Number Publication Date
IN2014MN02213A true IN2014MN02213A (pt) 2015-07-10

Family

ID=49550270

Family Applications (2)

Application Number Title Priority Date Filing Date
IN2213MUN2014 IN2014MN02213A (pt) 2012-05-10 2013-05-09
IN2214MUN2014 IN2014MN02214A (pt) 2012-05-10 2013-05-09

Family Applications After (1)

Application Number Title Priority Date Filing Date
IN2214MUN2014 IN2014MN02214A (pt) 2012-05-10 2013-05-09

Country Status (9)

Country Link
US (3) US9849088B2 (pt)
EP (2) EP2846772A4 (pt)
JP (4) JP2015516412A (pt)
CN (2) CN104427976B (pt)
AU (2) AU2013257546B2 (pt)
CA (2) CA2871821C (pt)
IN (2) IN2014MN02213A (pt)
RU (2) RU2678433C2 (pt)
WO (2) WO2013168172A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2871821C (en) * 2012-05-10 2021-01-12 Painreform Ltd. Depot formulations of a local anesthetic and methods for preparation thereof
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
EP3331516A4 (en) * 2015-07-13 2019-06-26 Neon Laboratories Ltd. HYPERBARE ROPIVACAINE HYDROCHLORIDE INJECTION SOLUTION AND PROCESS FOR THE PREPARATION THEREOF
CA3078555A1 (en) 2017-10-06 2019-04-11 Foundry Therapeutics, Inc. Implantable depots for the controlled release of therapeutic agents
US10716774B1 (en) 2018-01-05 2020-07-21 Yale Pharmaceuticals LLC Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability
WO2019226599A1 (en) * 2018-05-22 2019-11-28 Alkalidx, Inc. Diagnostics and treatments of anesthetic insensitive subjects
CN109316602A (zh) * 2018-11-13 2019-02-12 西安力邦医药科技有限责任公司 一种长效镇痛并促进伤口愈合的复方缓释递药系统的组方与应用
JP7378929B2 (ja) * 2018-12-27 2023-11-14 花王株式会社 リポソームの製造方法
CN111388418B (zh) * 2018-12-31 2022-09-06 北京泰德制药股份有限公司 一种含有罗哌卡因或其药用盐的药物组合物
WO2020259670A1 (zh) * 2019-06-28 2020-12-30 江苏恒瑞医药股份有限公司 一种缓释脂质组合物及其制备方法
EP4091612A4 (en) * 2020-01-14 2024-01-24 Shanghai Inst Materia Medica Cas PHARMACEUTICAL COMPOSITION OF LONG-ACTING ROPIVACAINE, PREPARATION METHOD AND USE THEREOF
WO2023043876A1 (en) * 2021-09-15 2023-03-23 Ocusoft, Inc. Ointments for treating dry skin
US20240065995A1 (en) * 2022-08-27 2024-02-29 Darren Alexander Rubin Injectable methods to treat deficiencies in glutathione metabolism and homocystinuria

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252793A (en) 1979-06-18 1981-02-24 American Lecithin Company Injectable lecithin preparation
JPH0753661B2 (ja) 1984-03-08 1995-06-07 フアレス フアーマスーチカル リサーチ エヌブイ プロ―リポソーム組成物及びリポソームの水性分散物を作る方法
US5173219A (en) 1986-02-12 1992-12-22 Research Development Foundation Uniform spherical multilamellar liposomes of defined and adjustable size distribution
US5723147A (en) 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
NZ223660A (en) 1987-03-05 1990-11-27 Liposome Co Inc Low toxicity drug-lipid complexes; methods of making them; and method of determining their toxicity
CH681427A5 (pt) 1987-07-01 1993-03-31 Zambon Spa
US5807572A (en) 1988-02-18 1998-09-15 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US5576017A (en) 1988-05-30 1996-11-19 Depotech Corporation Heterovesicular liposomes
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
AU2699892A (en) * 1991-10-04 1993-05-03 Gs Biochem Ab Particles, method of preparing said particles and uses thereof
SE9200952D0 (sv) * 1992-03-27 1992-03-27 Kabi Pharmacia Ab Pharmaceutical carrier system containing defined lipids
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
JPH08503950A (ja) 1992-12-02 1996-04-30 アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド 徐放性成長ホルモン含有マイクロスフェア
EP0695169B1 (en) 1993-04-22 2002-11-20 SkyePharma Inc. Multivesicular cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
US5455044A (en) 1993-05-14 1995-10-03 Depotech Corporation Method for treating neurological disorders
SE9302218D0 (sv) * 1993-06-28 1993-06-28 Ab Astra New use
DE69426884T2 (de) * 1993-07-08 2001-06-21 Liposome Co Inc Verfahren zum kontrollieren der liposomengrösse
EP0729351B1 (en) 1993-11-16 2000-09-13 SkyePharma Inc. Vesicles with controlled release of actives
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
DE69434258T2 (de) 1993-11-19 2006-01-19 Janssen Pharmaceutica N.V. Mikroverkapselte 1,2-benzazole
US5635206A (en) 1994-01-20 1997-06-03 Hoffmann-La Roche Inc. Process for liposomes or proliposomes
US5693337A (en) 1994-07-13 1997-12-02 Wakamoto Pharmaceutical Co., Ltd. Stable lipid emulsion
US5993850A (en) 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
HU223475B1 (hu) * 1994-10-24 2004-07-28 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Selegilint tartalmazó liposzoma-készítmény és eljárás ennek előállítására
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5981592A (en) 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US5955504A (en) 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
US6160018A (en) 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
WO1997007794A1 (fr) 1995-08-28 1997-03-06 Showa Yakuhin Kako Co., Ltd. Composition pour anesthesie locale
DE69511418T2 (de) 1995-10-28 2000-03-30 Braun Melsungen Ag Lokalanästhetika und/oder Zentralanalgetika enthaltende pharmazeutische Zusammensetzungen
US5744337A (en) * 1995-12-26 1998-04-28 The United States Of America As Represented By The Secretary Of The Navy Internal gelation method for forming multilayer microspheres and product thereof
FR2753626B1 (fr) 1996-09-20 1998-11-06 Centre International De Rech Dermatologiques Galderma Cird Galderma Nouvelles compositions topiques sous forme d'emulsion fluide h/e a forte teneur en glycol pro-penetrant
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
US5891467A (en) 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
AU7389098A (en) * 1997-05-16 1998-12-08 Brigham And Women's Hospital Local anesthetic formulations
GB2326337A (en) 1997-06-20 1998-12-23 Phares Pharma Holland Homogeneous lipid compositions for drug delivery
US6306432B1 (en) 1997-09-08 2001-10-23 Chiron Corporation High and low load formulations of IGF-I in multivesicular liposomes
US6106858A (en) 1997-09-08 2000-08-22 Skyepharma, Inc. Modulation of drug loading in multivescular liposomes
ATE535232T1 (de) 1997-09-18 2011-12-15 Pacira Pharmaceuticals Inc Retardierte freisetzung liposomaler anesthetischer zusammensetzungen
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
AU1297899A (en) * 1997-10-31 1999-05-24 Walter Reed Army Institute Of Research Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
AU752802C (en) 1997-11-14 2006-04-13 Pacira Pharmaceuticals, Inc. Production of multivesicular liposomes
BE1011899A6 (fr) 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
ES2325141T3 (es) 1998-07-17 2009-08-26 Pacira Pharmaceuticals, Inc. Composiciones biodegradables para la liberacion controlada de sustancias encapsuladas.
DE69822814T2 (de) * 1998-08-18 2005-01-27 Panacea Biotec Ltd. Zusammensetzung enthaltend Cyclosporin in einem hydrophilen Träger
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB9907715D0 (en) * 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
CA2375371A1 (en) 1999-06-04 2000-12-14 Skyepharma Inc. Oil-core compositions for the sustained release of hydrophobic drugs
KR100343125B1 (ko) 1999-09-14 2002-07-05 임정옥 도포용 리포좀형 혼합국소마취제 및 그 제조방법
EP1138313A1 (de) * 2000-03-28 2001-10-04 Primacare S.A. Pro-liposomen
US6761901B1 (en) 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
IL139177A0 (en) 2000-10-20 2001-11-25 S C Republic Dev S R L Sustained release drug delivery system
NZ529544A (en) 2001-05-31 2006-11-30 Skyepharma Inc Encapsulation of nanosuspensions in liposomes and microspheres
US20030099674A1 (en) 2001-08-11 2003-05-29 Chen Andrew X. Lyophilized injectable formulations containing paclitaxel or other taxoid drugs
BR0214679A (pt) 2001-12-03 2004-12-14 Novacea Inc Composições farmacêuticas compreendendo compostos a base de vitamina d ativa
EP1492522A4 (en) 2002-04-10 2009-01-14 Conforma Therapeutics Corp ANSAMYCIN FORMULATIONS AND METHODS OF MAKING AND USING THE SAME
US7229630B2 (en) 2002-06-20 2007-06-12 Novalar Pharmaceuticals, Inc. Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
US20030236306A1 (en) 2002-06-20 2003-12-25 Chen Andrew X. Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
AU2003266159A1 (en) 2002-09-16 2004-04-30 Zicam, Llc. System and method for delivering a composition to the nasal membrane
WO2004032845A2 (en) 2002-10-07 2004-04-22 Encore Pharmaceuticals, Inc. R-nsaid esters and their use
US20050026877A1 (en) 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20050020546A1 (en) 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060189586A1 (en) 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
US20050049209A1 (en) 2003-08-06 2005-03-03 Chen Andrew Xian Pharmaceutical compositions for delivering macrolides
US20050118206A1 (en) 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
US7968122B2 (en) 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
US20050186230A1 (en) 2004-01-23 2005-08-25 Sd Pharmaceuticals, Inc. Elemene compositions containing liquid oil
EP1729784A1 (en) 2004-02-23 2006-12-13 Attenuon, LLC Formulations of thiomolybdate or thiotungstate compounds and uses thereof
AU2005249274B2 (en) * 2004-06-04 2011-02-24 Camurus Ab Liquid depot formulations
CN101027065A (zh) * 2004-06-15 2007-08-29 陈献 磷脂组合物及其制备和使用方法
US7871632B2 (en) 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
AU2005269383A1 (en) 2004-07-28 2006-02-09 Sd Pharmaceuticals, Inc. Stable injectable composition of alpha tocopheryl succinate, analogues and salts thereof
US8557861B2 (en) 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
NZ565108A (en) 2005-07-07 2011-10-28 Farnam Co Inc Sustained release pharmaceutical compositions for highly water soluble drugs
WO2007041476A2 (en) * 2005-09-30 2007-04-12 Vyteris, Inc. Indications for local transport of anaesthetic agents by electrotransport devices
CN101321518A (zh) 2005-12-02 2008-12-10 阿德文特克斯药物有限公司 5,10-亚甲基四氢叶酸盐的稳定药物组合物
CN100486569C (zh) 2006-01-06 2009-05-13 中国药科大学 一种多烯紫杉醇自组装前体脂质体及其制备方法
CN100518738C (zh) * 2006-01-06 2009-07-29 中国药科大学 一种含喜树碱类药物的自组装前体脂质体及其制备方法
CN100563715C (zh) 2006-01-06 2009-12-02 中国药科大学 一种紫杉醇自组装前体脂质体及其制备方法
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
CA2672024C (en) * 2006-12-07 2014-07-08 Lyotropic Therapeutics, Inc. Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use
EP1938801A1 (en) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
WO2008088756A1 (en) 2007-01-12 2008-07-24 Bridge Pharma, Inc. Dermal compositions of substituted amides and the use thereof as medication for pain and pruritus
AU2008223091B2 (en) 2007-03-02 2014-04-24 Farnam Companies, Inc. Sustained release pellets comprising wax-like material
CA2681302C (en) 2007-03-19 2013-07-23 Dhiraj Khattar Proliposomal and liposomal compositions of poorly water-soluble compounds
BRPI0704542B8 (pt) 2007-05-15 2021-05-25 Univ Estadual Campinas Unicamp composição farmacêutica, processo de obtenção da composição farmacêutica, uso de uma quantidade farmaceuticamente eficaz de anestésico e agente gelificante, produto e método de tratamento
RU2429242C2 (ru) * 2007-05-30 2011-09-20 Учреждение Российской Академии Наук Институт Проблем Химической Физики Ран (Ипхф Ран) Применение тетранитрозильного комплекса железа с тиофенолом в качестве противоопухолевого лекарственного средства
HUP0700426A2 (en) 2007-06-19 2010-03-29 Invencio 21 Gyogyhatasu Keszit Liposomal compound
WO2009011861A1 (en) 2007-07-16 2009-01-22 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
FR2924024B1 (fr) 2007-11-27 2012-08-17 Centre Nat Rech Scient Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
CN101485629B (zh) 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
JP5608653B2 (ja) 2008-09-04 2014-10-15 ファーナム・カンパニーズ・インコーポレーテッド チュアブルな徐放性製剤
WO2010042212A2 (en) 2008-10-10 2010-04-15 Dara Biosciences, Inc. Methods for treating or preventing pain using spicamycin derivatives
US20100305500A1 (en) 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
WO2011031462A2 (en) 2009-08-25 2011-03-17 Latitude Pharmaceuticals Incorporated Compositions for delivery of insoluble agents
EP2336286A1 (en) * 2009-12-18 2011-06-22 The Procter & Gamble Company Composition comprising microcapsules
CN102933200B (zh) 2009-12-18 2015-11-25 莱迪杜德制药公司 包含磷脂的单相凝胶组合物
WO2011096953A1 (en) 2010-02-05 2011-08-11 Cenerx Biopharma, Inc. Oral antidepressant formulation with reduced excipient load
US20140066481A1 (en) 2010-04-01 2014-03-06 Pharmanest Ab Water-Free Pharmaceutical Compositions Suitable for Local Anaesthetics
EP2555752B1 (en) 2010-04-09 2019-06-26 Pacira Pharmaceuticals, Inc. Method for formulating multivesicular liposomes
US9770414B2 (en) 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
WO2011153513A2 (en) 2010-06-03 2011-12-08 Latitude Pharma Nanoemulsion composition containing vitamin k
MX340819B (es) 2010-06-29 2016-07-26 Poniard Pharmaceuticals Inc * Formulacion oral de inhibidores de quinasa.
EP2593089B1 (en) 2010-07-14 2018-04-04 Senju Pharmaceutical Co., Ltd. Solid dispersion of alfa-ketoamide derivative
AU2010359346B2 (en) 2010-08-20 2015-01-29 Dr. Reddy's Laboratories Sa Phospholipid depot
US20130203701A1 (en) 2010-09-17 2013-08-08 Maine Natural Health, Inc. Compositions containing omega-3 oil and uses thereof
AU2011317237B2 (en) 2010-10-22 2015-02-05 Dr. Reddy's Laboratories Sa Use of storage stable viscous phospholipid depot to treat wounds
US10610486B2 (en) 2010-10-28 2020-04-07 Pacira Pharmaceuticals, Inc. Sustained release formulation of a non-steroidal anti-inflammatory drug
WO2012170796A1 (en) 2011-06-09 2012-12-13 Amylin Pharmaceuticals, Inc. Gel compositions
CA2871821C (en) * 2012-05-10 2021-01-12 Painreform Ltd. Depot formulations of a local anesthetic and methods for preparation thereof

Also Published As

Publication number Publication date
JP6577548B2 (ja) 2019-09-18
AU2013257546B2 (en) 2017-12-14
US20150111923A1 (en) 2015-04-23
EP2846772A4 (en) 2015-12-30
EP2846773A4 (en) 2015-12-30
CN104427976A (zh) 2015-03-18
US9668974B2 (en) 2017-06-06
CA2871820C (en) 2020-11-03
RU2014144501A (ru) 2016-07-10
JP2015516411A (ja) 2015-06-11
WO2013168167A1 (en) 2013-11-14
US20180049985A1 (en) 2018-02-22
EP2846773A1 (en) 2015-03-18
IN2014MN02214A (pt) 2015-07-17
CN104427976B (zh) 2018-04-24
RU2014144500A (ru) 2016-07-10
RU2664700C2 (ru) 2018-08-21
EP2846772A1 (en) 2015-03-18
RU2678433C2 (ru) 2019-01-29
JP2017222729A (ja) 2017-12-21
JP2015516412A (ja) 2015-06-11
US10206876B2 (en) 2019-02-19
WO2013168172A1 (en) 2013-11-14
US9849088B2 (en) 2017-12-26
US20150148325A1 (en) 2015-05-28
AU2013257546A1 (en) 2014-11-27
CA2871821A1 (en) 2013-11-14
JP6574228B2 (ja) 2019-09-11
CN104427977B (zh) 2018-02-02
AU2013257608A1 (en) 2014-11-27
CA2871820A1 (en) 2013-11-14
JP2018035179A (ja) 2018-03-08
CA2871821C (en) 2021-01-12
AU2013257608B2 (en) 2017-12-14
CN104427977A (zh) 2015-03-18

Similar Documents

Publication Publication Date Title
IN2014MN02213A (pt)
AU2018256640A1 (en) Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
MX2021006035A (es) Formulaciones cannabinoides estables.
EP4285928A3 (en) Anti-pdl1 antibody formulations
MX2019003693A (es) Formulaciones de insulina de accion prolongada.
MX2014011181A (es) Microemulsiones basadas en ciclodextrina y usos dermatologicos de las mismas.
MX2015017964A (es) Inhibidores de bromodominio.
MX2016005395A (es) Formulacion estable de insulina glulisina.
MX351584B (es) Formulacion farmaceutica acuosa de tapentadol para administracion oral.
MD20150050A2 (ro) Soluţii midriatice şi antiinflamatorii stabile fără conservanţi pentru injectare
MX2021010359A (es) Una composicion farmaceutica para reducir la grasa localizada y sus usos.
EP4360621A3 (en) Formulations of bendamustine
IN2014DN00277A (pt)
IN2014MN01470A (pt)
MX2016011290A (es) Composiciones de ester de colina de acido lipoico y metodos de uso.
DOP2017000307A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma.
PH12015502556A1 (en) Modified release formulation
EP2981258B8 (en) Pharmaceutical formulations for subcutaneous administration of furosemide
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
WO2013100869A3 (en) Lipid-based nanocarrier systems for using cancer treatment
MX2016004328A (es) Inmunopotenciador.
BR112017019364A2 (pt) dispersões sólidas
IN2014DN09246A (pt)
GB201204632D0 (en) Delivery system